Progenity, a San Diego molecular diagnostics company focused on women’s health, reproductive medicine, and oncology, has raised $125 million in a Series B financing led by New York’s Athyrium Capital Management, an earlier investor. The financing marks one of the biggest life sciences deal involving a San Diego company this year. Proceeds from the financing, […]
NYS Entity Status
NYS Filing Date
JANUARY 29, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2013 - HEALTH DIAGNOSTICS MANAGEMENT, LLC
Around the Web
- Progenity Raises $125M to Expand Diagnostics for Women’s Health
By Bruce V. Bigelow - Tuesday Nov 7, 2017
- Blink Health Ends Pact With Express Scripts for Lilly Insulin Price Discounts
Tuesday Jun 13, 2017
Blink Health LLC, a provider of consumer price discounts for prescription drugs, said it has terminated its relationship with Express Scripts Holding Co., a pharmacy-benefit manager that helped arrange the new price break for Lilly’s insulin.
- Adult ADHD Diagnostic Perspectives
Wednesday Oct 11, 2017
Dr. Adler provides a detailed review of the diagnostic criteria associated with adult attention-deficit / hyperactivity disorder (ADHD) due to the complex constellation of symptoms that mimic or confound other mental health issues.
- Heart and Asthma Monitors? There’s an App for That
By CAROL POGASH - Wednesday Aug 9, 2017
Start-ups by young Berkeley engineers are marketing devices for home use that will help heart patients and asthmatic children manage their conditions.
- With Health Law in Flux, Insurers Scramble to Meet Filing Deadline
By REED ABELSON - Wednesday Jun 21, 2017
Anthem, a major player in the Obamacare exchanges, announced that it would withdraw from Wisconsin and Indiana next year, along with Ohio.
- Investors bet big on AI for health diagnostics
By Jonathan Norris, Silicon Valley Bank - Saturday Aug 5, 2017
GUEST: We’re seeing a new wave of venture investments in healthtech companies — especially those with strong artifical intelligence and machine learning components. Led by some of the world’s largest biopharma companies and tech-focused venture capitalists, these investments are backing efforts to speed drug discovery, improve tests and treatments, and further medical research. For now, most […]